Intracellular osteopontin potentiates the immunosuppressive activity of mesenchymal stromal cells.

Publisher: BioMed Central Country of Publication: England NLM ID: 101527581 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-6512 (Electronic) Linking ISSN: 17576512 NLM ISO Abbreviation: Stem Cell Res Ther Subsets: MEDLINE

Original Publication: London : BioMed Central

Mesenchymal Stem Cells*/metabolism ; Mesenchymal Stem Cells*/immunology ; Osteopontin*/metabolism ; Osteopontin*/genetics ; STAT1 Transcription Factor*/metabolism; Animals ; Female ; Male ; Mice ; Cell Proliferation ; Mesenchymal Stem Cell Transplantation/methods ; Mice, Inbred C57BL ; Nitric Oxide Synthase Type II/metabolism ; Nitric Oxide Synthase Type II/genetics ; T-Lymphocytes/metabolism ; T-Lymphocytes/immunology

Introduction: Mesenchymal stromal cell (MSC)-based cell therapy is a promising approach for various inflammatory disorders based on their immunosuppressive capacity. Osteopontin (OPN) regulates several cellular functions including tissue repair, bone metabolism and immune reaction. However, the biological function of OPN in regulating the immunosuppressive capacity of MSCs remains elusive.
Objectives: This study aims to highlight the underlying mechanism of the proinflammatory cytokines affect the therapeutic ability of MSCs through OPN.
Methods: MSCs in response to the proinflammatory cytokines were collected to determine the expression profile of OPN. In vitro T-cell proliferation assays and gene editing were performed to check the role and mechanisms of OPN in regulating the immunosuppressive capacity of MSCs. Inflammatory disease mouse models were established to evaluate the effect of OPN on improving MSC-based immunotherapy.
Results: We observed that OPN, including its two isoforms iOPN and sOPN, was downregulated in MSCs upon proinflammatory cytokine stimulation. Interestingly, iOPN, but not sOPN, greatly enhanced the immunosuppressive activity of MSCs on T-cell proliferation and thus alleviated the inflammatory pathologies of hepatitis and colitis. Mechanistically, iOPN interacted with STAT1 and mediated its deubiquitination, thereby inducing the master immunosuppressive mediator inducible nitric oxide synthase (iNOS) in MSCs. In addition, iOPN expression was directly downregulated by activated STAT1, which formed a negative feedback loop to restrain MSC immunosuppressive capacity.
Conclusion: Our findings demonstrated that iOPN expression modulation in MSCs is a novel strategy to improve MSC-based immunotherapy.
(© 2024. The Author(s).)

Cell Stem Cell. 2008 Feb 7;2(2):141-50. (PMID: 18371435)
Hepatology. 2014 Feb;59(2):671-82. (PMID: 23929707)
Nat Med. 2011 Nov 20;17(12):1594-601. (PMID: 22101767)
Cell Death Differ. 2021 Feb;28(2):640-656. (PMID: 32814877)
J Dent Res. 2015 Dec;94(12):1638-45. (PMID: 26341976)
J Immunol. 2005 Jul 1;175(1):523-30. (PMID: 15972688)
Int J Mol Sci. 2016 May 05;17(5):. (PMID: 27164080)
Mol Ther. 2012 Jan;20(1):14-20. (PMID: 22008910)
Eur J Immunol. 2007 Feb;37(2):338-50. (PMID: 17274000)
Nat Methods. 2013 Jul;10(7):676-82. (PMID: 23749301)
Blood. 2005 Aug 15;106(4):1232-9. (PMID: 15845900)
Nature. 2011 Jun 15;474(7351):307-17. (PMID: 21677747)
Signal Transduct Target Ther. 2022 Mar 21;7(1):92. (PMID: 35314676)
J Mol Med (Berl). 2019 May;97(5):605-618. (PMID: 30903229)
Expert Opin Ther Targets. 2013 Mar;17(3):243-54. (PMID: 23293906)
Immunity. 2014 Jun 19;40(6):880-95. (PMID: 24882218)
Theranostics. 2020 Oct 30;10(26):12204-12222. (PMID: 33204338)
Periodontol 2000. 2013 Oct;63(1):198-216. (PMID: 23931061)
Bone. 2005 Jun;36(6):1047-55. (PMID: 15869916)
Nat Immunol. 2014 Nov;15(11):1009-16. (PMID: 25329189)
Immunol Res. 2011 Apr;49(1-3):160-72. (PMID: 21136203)
Cancer Lett. 2021 Jan 28;497:28-40. (PMID: 33069768)
Cell Mol Immunol. 2021 Jun;18(6):1476-1488. (PMID: 31900460)
J Biol Chem. 2013 Apr 19;288(16):11074-9. (PMID: 23449975)
Cell Death Differ. 2014 Nov;21(11):1758-68. (PMID: 25034782)
Cell Mol Immunol. 2018 Apr;15(4):405-407. (PMID: 28967877)
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):494-9. (PMID: 25550515)
Stem Cells. 2014 Feb;32(2):327-37. (PMID: 24123709)
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):E856-65. (PMID: 24550510)
Nat Rev Nephrol. 2018 Aug;14(8):493-507. (PMID: 29895977)
World J Gastroenterol. 2012 Jan 14;18(2):119-25. (PMID: 22253517)
Int J Mol Sci. 2020 May 01;21(9):. (PMID: 32369982)
J Immunol. 2011 Jan 1;186(1):19-23. (PMID: 21135164)
Autophagy. 2014 Jul;10(7):1301-15. (PMID: 24905997)
Stem Cells. 2006 Feb;24(2):386-98. (PMID: 16123384)
Pharmacol Res. 2019 Jun;144:235-244. (PMID: 31028902)
Cell Stem Cell. 2022 Nov 3;29(11):1515-1530. (PMID: 36332569)
Matrix Biol. 2014 Jul;37:131-41. (PMID: 24657887)
Cytokine Growth Factor Rev. 2008 Oct-Dec;19(5-6):333-45. (PMID: 18952487)
Cytokine Growth Factor Rev. 2019 Dec;50:19-28. (PMID: 31126876)
Sci Rep. 2016 Mar 30;6:23771. (PMID: 27026194)
Pathol Int. 2011 May;61(5):265-80. (PMID: 21501293)
Cell Death Dis. 2014 Jan 23;5:e1009. (PMID: 24457953)
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17101-6. (PMID: 16286640)
Neoplasia. 2007 Sep;9(9):699-706. (PMID: 17898865)
J Immunol. 2007 Feb 1;178(3):1870-81. (PMID: 17237438)

82271589 National Natural Science Foundation of China; 82300584 National Natural Science Foundation of China; 82000567 National Natural Science Foundation of China; 82000553 National Natural Science Foundation of China; 82001739 National Natural Science Foundation of China; 82070191 National Natural Science Foundation of China; 82071727 National Natural Science Foundation of China; 2018YFA010720 National Key R&D Program of China

Keywords: Immunosuppression; Inflammation; Intracellular osteopontin; Mesenchymal stem cells; STAT1

EC 1.14.13.39 (Nitric Oxide Synthase Type II)
106441-73-0 (Osteopontin)
0 (STAT1 Transcription Factor)
0 (Spp1 protein, mouse)

Date Created: 20241015 Date Completed: 20241016 Latest Revision: 20241020

20250114

PMC11475537

10.1186/s13287-024-03979-8

39407354